Bioretec as an investment
We are a global pioneer in developing and manufacturing absorbable orthopedic implants, founded in 2003 in Finland. Our unique expertise in combining materials engineering and biochemistry offers a superior solution for bone fracture treatment compared to traditional alternatives.
Our future growth strategy is focused on the development and commercialization of the RemeOs product series. The first RemeOs™ product market authorization was received in the U.S. in March 2023, and in Europe, the product portfolio received a CE mark approval in January 2025. The next-generation magnesium-based RemeOs implants are absorbed and replaced by bone, eliminating the need for removal surgery while facilitating fracture healing. Our Activa products are already used in more than 40 countries globally and are trusted by hundreds of thousands of adult and pediatric patients.
The market for orthopedic trauma products is large and steadily growing. In recent years, the use of absorbable orthopedic implants has become more common, driven by their ability to improve patient quality of life and save healthcare costs.
Bioretec as an investment
Attractive market
Bioretec has a large and steadily growing addressable market of ~USD 9 billion with increasing demand for orthopedic implants. The market for the absorbable trauma screws alone is expected to have a CAGR of 9.4% in the US until 2033.
Superior solution for patient healing
Magnesium based absorbable implants promote bone healing and eliminate need for implant removal. RemeOs products can carry more load and are well-suited for treating larger bone fractures. Activa products facilitate healing in orthopedic indications where carrying capacity is not required.
RemeOs™ Trauma Screw market authorizations in the U.S. and EU
Bioretec aims for strong growth with its next-generation RemeOs™ product family. RemeOs Trauma Screw is the first and currently only absorbable metal product on the U.S. market. The European CE mark enables commercialization of the product family in Europe and other countries that recognize the CE mark.
Strong pipeline for launching additional products in coming years
Market authorizations in the U.S. and EU pave the way for next product launches. Bioretec plans to launch DrillPin in 2025, staples in 2026, plates in 2027, and the IM-Nail and Spinal Cage after 2028.
Experienced management team executing commercialization plan
Bioretec’s team has world-class expertise and a long track record of successful product development and regulatory approval processes. The management is supported by Bioretec’s Scientific Advisory Board (SAB) consisting of leading experts in their fields.
Connect
Contact us© 2025 Bioretec Ltd. All rights reserved. Specifications are subject to change without notice.
Privacy Policy